Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 3/20 | 0.79 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.79 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.79 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.79 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.79 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.79 |
| ▸ | FXYD2 | P54710 | 3/20 | 0.79 |
| ▸ | ATP1A4 | Q13733 | 3/20 | 0.79 |
| ▸ | MAOA | P21397 | 11/20 | 0.75 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151934 | 0.89 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL12359896 | 0.86 | MAOA (0.69) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL1788224 | 0.86 | MAOA (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL8958340 | 0.86 | MAOA (0.74) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL23240848 | 0.86 | ATP1A1 (0.71) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL5141096 | 0.85 | ATP1A1 (0.59) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL23240708 | 0.84 | ATP1A1 (0.73) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL31258561 | 0.83 | MAOA (0.65) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL7237614 | 0.83 | MAOA (0.65) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL30738503 | 0.82 | MAOA (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888052-A4 | XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES | INTERLAB CORP (US) | 2002-05-22 | — | — | EP | claimed |
| EP-0888052-A1 | XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES | INTERLAB CORPORATION (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997034482-A1 | XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES | INTERLAB CORP. (US) | 1997-09-25 | — | — | WO | claimed |
| US-20230130102-A1 | Na/K-ATPase LIGANDS AND USE THEREOF FOR TREATMENT OF CANCER | MARSHALL UNIVERSITY RESEARCH CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-20230130102-A1 | Na/K-ATPase LIGANDS AND USE THEREOF FOR TREATMENT OF CANCER | MARSHALL UNIVERSITY RESEARCH CORPORATION | 2023-04-27 | — | — | US | disclosed |
| WO-2021072083-A1 | Na/K-ATPase LIGANDS AND USE THEREOF FOR TREATMENT OF CANCER | MARSHALL UNIVERSITY RESEARCH CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |
| US-6613797-B2 | New xanthone derivatives useful for treating protozoan diseases | INTERLAB, INC. | 2003-09-02 | — | — | US | disclosed |
| EP-0888052-A4 | XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES | INTERLAB CORP (US) | 2002-05-22 | — | — | EP | disclosed |
| US-20020055644-A1 | Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins | INTERLAB, INC. | 2002-05-09 | — | — | US | disclosed |
| WO-2001041773-A1 | XANTHONE ANALOGS FOR TREATING INFECTIOUS DISEASES AND COMPLEXATION OF HEME AND PORPHYRINS | INTERLAB, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-0888052-A1 | XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES | INTERLAB CORPORATION (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034482-A1 | XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES | INTERLAB CORP. (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130102-A1 | Na/K-ATPase LIGANDS AND USE THEREOF FOR TREATMENT OF CANCER | ATP1A1, ATP1A2, ATP4A | ATP1A1 1/4885ATP1B1 4/4885ATP1A3 9/4885 |
| US-20020055644-A1 | Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins | XPA, XDH, HMOX1 | ATP1A1 2015/4885ATP1B1 2280/4885ATP1A3 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.